Referencias
Artículos principales
Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barré syndrome. Lancet. 2016 Aug 13;388(10045):717-27.Texto completo Resumen
Stowe J, Andrews N, Wise L, et al. Investigation of the temporal association of Guillain-Barré syndrome with influenza vaccine and influenzalike illness using the United Kingdom General Practice Research Database. Am J Epidemiol. 2009 Feb 1;169(3):382-8.Texto completo Resumen
Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2014 Sep 19;(9):CD002063.Texto completo Resumen
Lawn ND, Fletcher DD, Henderson RD, et al. Anticipating mechanical ventilation in Guillain-Barré syndrome. Arch Neurol. 2001 Jun;58(6):893-8.Texto completo Resumen
Hughes RA, Brassington R, Gunn AA, et al. Corticosteroids for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2016 Oct 24;(10):CD001446.Texto completo Resumen
Walgaard C, Jacobs BC, Lingsma HF, et al. Second intravenous immunoglobulin dose in patients with Guillain-Barré syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2021 Apr;20(4):275-83. Resumen
Artículos de referencia
1. Hadden RD, Hughes RA. Management of inflammatory neuropathies. J Neurol Neurosurg Psychiatry. 2003 Jun;74(suppl 2):ii9-14.Texto completo Resumen
2. Hiraga A, Mori M, Ogawara K, et al. Recovery patterns and long term prognosis for axonal Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry. 2005 May;76(5):719-22.Texto completo Resumen
3. Guillain G, Barré JA, Strohl A. Radiculoneuritis syndrome with hyperalbuminosis of cerebrospinal fluid without cellular reaction. Notes on clinical features and graphs of tendon reflexes. 1916 [in French]. Ann Med Interne (Paris). 1999 Jan;150(1):24-32. Resumen
4. Asbury AK, Arnason BG, Adams RD. The inflammatory lesion in idiopathic polyneuritis. Its role in pathogenesis. Medicine (Baltimore). 1969 May;48(3):173-215. Resumen
5. Yuki N, Hartung HP. Guillain-Barré syndrome. N Engl J Med. 2012 Jun 14;366(24):2294-304. Resumen
6. Bickerstaff ER. Brain-stem encephalitis; further observations on a grave syndrome with benign prognosis. Br Med J. 1957 Jun 15;1(5032):1384-7.Texto completo Resumen
7. Mericle RA, Triggs WJ. Treatment of acute pandysautonomia with intravenous immunoglobulin. J Neurol Neurosurg Psychiatry. 1997 May;62(5):529-31.Texto completo Resumen
8. Anzai T, Uematsu D, Takahashi K, et al. Guillain-Barré syndrome with bilateral tonic pupils. Intern Med. 1994 Apr;33(4):248-51.Texto completo Resumen
9. Ropper AH. Further regional variants of acute immune polyneuropathy. Bifacial weakness or sixth nerve paresis with paresthesias, lumbar polyradiculopathy, and ataxia with pharyngeal-cervical-brachial weakness. Arch Neurol. 1994 Jul;51(7):671-5. Resumen
10. Webb AJ, Brain SA, Wood R, et al. Seasonal variation in Guillain-Barré syndrome: a systematic review, meta-analysis and Oxfordshire cohort study. J Neurol Neurosurg Psychiatry. 2015 Nov;86(11):1196-201.Texto completo Resumen
11. Leonhard SE, Mandarakas MR, Gondim FAA, et al. Diagnosis and management of Guillain-Barré syndrome in ten steps. Nat Rev Neurol. 2019 Nov;15(11):671-83.Texto completo Resumen
12. Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barré syndrome. Lancet. 2016 Aug 13;388(10045):717-27.Texto completo Resumen
13. Poropatich KO, Walker CL, Black RE. Quantifying the association between Campylobacter infection and Guillain-Barré syndrome: a systematic review. J Health Popul Nutr. 2010 Dec;28(6):545-52.Texto completo Resumen
14. The French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome. Appropriate number of plasma exchanges in Guillain-Barré syndrome. Ann Neurol. 1997 Mar;41(3):298-306. Resumen
15. Winer JB, Hughes RA, Anderson MJ, et al. A prospective study of acute idiopathic neuropathy. II. Antecedent events. J Neurol Neurosurg Psychiatry. 1988 May;51(5):613-8.Texto completo Resumen
16. Jones HR Jr. Guillain-Barré syndrome in children. Curr Opin Pediatr. 1995 Dec;7(6):663-8. Resumen
17. Ho TW, Mishu B, Li CY, et al. Guillain-Barré syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain. 1995 Jun;118 ( Pt 3):597-605. Resumen
18. Jacobs BC, van Doorn PA, Schmitz PI, et al. Campylobacter jejuni infections and anti-GM1 antibodies in GBS. Ann Neurol. 1996 Aug;40(2):181-7. Resumen
19. Lyu RK, Tang LM, Cheng SY, et al. Guillain-Barré syndrome in Taiwan: a clinical study of 167 patients. J Neurol Neurosurg Psychiatry. 1997 Oct;63(4):494-500.Texto completo Resumen
20. Barbi L, Coelho AVC, Alencar LCA, et al. Prevalence of Guillain-Barré syndrome among Zika virus infected cases: a systematic review and meta-analysis. Braz J Infect Dis. 2018 Mar-Apr;22(2):137-41.Texto completo Resumen
21. Capasso A, Ompad DC, Vieira DL, et al. Incidence of Guillain-Barré Syndrome (GBS) in Latin America and the Caribbean before and during the 2015-2016 Zika virus epidemic: A systematic review and meta-analysis. PLoS Negl Trop Dis. 2019 Aug;13(8):e0007622.Texto completo Resumen
22. Cardona-Ospina JA, Henao-SanMartin V, Acevedo-Mendoza WF, et al. Fatal Zika virus infection in the Americas: A systematic review. Int J Infect Dis. 2019 Nov;88:49-59.Texto completo Resumen
23. Uncini A, Vallat JM, Jacobs BC. Guillain-Barré syndrome in SARS-CoV-2 infection: an instant systematic review of the first six months of pandemic. J Neurol Neurosurg Psychiatry. 2020 Oct;91(10):1105-10.Texto completo Resumen
24. Caress JB, Castoro RJ, Simmons Z, et al. COVID-19-associated Guillain-Barré syndrome: The early pandemic experience. Muscle Nerve. 2020 Oct;62(4):485-91.Texto completo Resumen
25. Hasan I, Saif-Ur-Rahman KM, Hayat S, et al. Guillain-Barré syndrome associated with SARS-CoV-2 infection: A systematic review and individual participant data meta-analysis. J Peripher Nerv Syst. 2020 Dec;25(4):335-43.Texto completo Resumen
26. European Medicines Agency. Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 3-6 May 2021. May 2021 [internet publication].Texto completo
27. Geleijns K, Emonts M, Laman JD, et al. Genetic polymorphisms of macrophage-mediators in Guillain-Barré syndrome. J Neuroimmunol. 2007 Oct;190(1-2):127-30. Resumen
28. Zhang L, Liu L, Li H, et al. Association of CD1 and FcγR gene polymorphisms with Guillain-Barré syndrome susceptibility: a meta-analysis. Neurol Sci. 2018 Dec;39(12):2141-9. Resumen
29. Schwerer B. Antibodies against gangliosides: a link between preceding infection and immunopathogenesis of Guillain-Barré syndrome. Microbes Infect. 2002 Mar;4(3):373-84. Resumen
30. Hadden RD, Karch H, Hartung HP, et al; Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Preceding infections, immune factors, and outcome in Guillain-Barré syndrome. Neurology. 2001 Mar 27;56(6):758-65. Resumen
31. Van Koningsveld R, Van Doorn PA, Schmitz PI, et al. Mild forms of Guillain-Barré syndrome in an epidemiologic survey in The Netherlands. Neurology. 2000 Feb 8;54(3):620-5. Resumen
32. Visser LH, Van der Meché FG, Van Doorn PA, et al. Guillain-Barré syndrome without sensory loss (acute motor neuropathy). A subgroup with specific clinical, electrodiagnostic and laboratory features. Dutch Guillain-Barré Study Group. Brain. 1995 Aug;118(Pt 4):841-7. Resumen
33. Griffin JW, Li CY, Ho TW, et al. Pathology of the motor-sensory axonal Guillain-Barré syndrome. Ann Neurol. 1996 Jan;39(1):17-28. Resumen
34. Almqvist J, Granberg T, Tzortzakakis A, et al. Neurological manifestations of coronavirus infections - a systematic review. Ann Clin Transl Neurol. 2020 Oct;7(10):2057-71.Texto completo Resumen
35. Abu-Rumeileh S, Abdelhak A, Foschi M, et al. Guillain-Barré syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases. J Neurol. 2021 Apr;268(4):1133-70.Texto completo Resumen
36. Langmuir AD, Bregman DJ, Kurland LT, et al. An epidemiologic and clinical evaluation of Guillain-Barré syndrome reported in association with the administration of swine influenza vaccines. Am J Epidemiol. 1984 Jun;119(6):841-79. Resumen
37. Hemachudha T, Griffin DE, Chen WW, et al. Immunologic studies of rabies vaccination-induced Guillain-Barré syndrome. Neurology. 1988 Mar;38(3):375-8. Resumen
38. Stowe J, Andrews N, Wise L, et al. Investigation of the temporal association of Guillain-Barré syndrome with influenza vaccine and influenzalike illness using the United Kingdom General Practice Research Database. Am J Epidemiol. 2009 Feb 1;169(3):382-8.Texto completo Resumen
39. Centers for Disease Control and Prevention. Guillain-Barré syndrome and Menactra meningococcal vaccine FAQs. Aug 2020 [internet publication].Texto completo
40. D'alò GL, Zorzoli E, Capanna A, et al. Frequently asked questions on seven rare adverse events following immunization. J Prev Med Hyg. 2017 Mar;58(1):E13-E26.Texto completo Resumen
41. Sanz Fadrique R, Martín Arias L, Molina-Guarneros JA, et al. Guillain-Barré syndrome and influenza vaccines: current evidence. Rev Esp Quimioter. 2019 Aug;32(4):288-95.Texto completo Resumen
42. Martín Arias LH, Sanz R, Sáinz M, et al. Guillain-Barré syndrome and influenza vaccines: a meta-analysis. Vaccine. 2015 Jul 17;33(31):3773-8. Resumen
43. Malkki H. CNS infections: Zika virus infection could trigger Guillain-Barré syndrome. Nat Rev Neurol. 2016 Apr;12(4):187.Texto completo Resumen
44. Anaya JM, Ramirez-Santana C, Salgado-Castaneda I, et al. Zika virus and neurologic autoimmunity: the putative role of gangliosides. BMC Med. 2016 Mar 21;14:49.Texto completo Resumen
45. Krauer F, Riesen M, Reveiz L, et al; WHO Zika Causality Working Group. Zika virus infection as a cause of congenital brain abnormalities and Guillain-Barré syndrome: systematic review. PLoS Med. 2017 Jan 3;14(1):e1002203.Texto completo Resumen
46. Ralapanawa DM, Kularatne SA, Jayalath WA. Guillain-Barre syndrome following dengue fever and literature review. BMC Res Notes. 2015 Nov 27;8:729.Texto completo Resumen
47. Oehler E, Fournier E, Leparc-Goffart I, et al. Increase in cases of Guillain-Barré syndrome during a Chikungunya outbreak, French Polynesia, 2014 to 2015. Euro Surveill. 2015;20(48):30079. Resumen
48. Simon O, Billot S, Guyon D, et al. Early Guillain-Barré syndrome associated with acute dengue fever. J Clin Virol. 2016 Apr;77:29-31. Resumen
49. Cerny T, Schwarz M, Schwarz U, et al. The range of neurological complications in chikungunya fever. Neurocrit Care. 2017 Dec;27(3):447-57.Texto completo Resumen
50. Chevret S, Hughes RA, Annane D. Plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2017 Feb 27;(2):CD001798.Texto completo Resumen
51. Hughes RA, Hadden RD, Gregson NA, et al. Pathogenesis of Guillain-Barré syndrome. J Neuroimmunol. 1999 Dec;100(1-2):74-97. Resumen
52. Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2014 Sep 19;(9):CD002063.Texto completo Resumen
53. Yuki N, Yoshino H, Sato S, et al. Acute axonal polyneuropathy associated with anti-GM1 antibodies following Campylobacter enteritis. Neurology. 1990 Dec;40(12):1900-2. Resumen
54. Ogawara K, Kuwabara S, Mori M, et al. Axonal Guillain-Barre syndrome: relation to anti-ganglioside antibodies and Campylobacter jejuni infection in Japan. Ann Neurol. 2000 Oct;48(4):624-31. Resumen
55. Jacobs BC, Hazenberg MP, van Doorn PA, et al. Cross-reactive antibodies against gangliosides and Campylobacter jejuni lipopolysaccharides in patients with Guillain-Barré or Miller Fisher syndrome. J Infect Dis. 1997 Mar;175(3):729-33. Resumen
56. Walsh FS, Cronin M, Koblar S, et al. Association between glycoconjugate antibodies and Campylobacter infection in patients with Guillain-Barré syndrome. J Neuroimmunol. 1991 Oct;34(1):43-51. Resumen
57. Gregson NA, Koblar S, Hughes RA. Antibodies to gangliosides in Guillain-Barré syndrome: specificity and relationship to clinical features. Q J Med. 1993 Feb;86(2):111-7. Resumen
58. Yuki N, Yoshino H, Sato S, et al. Severe acute axonal form of Guillain-Barré syndrome associated with IgG anti-GD1a antibodies. Muscle Nerve. 1992 Aug;15(8):899-903. Resumen
59. Gregson NA, Jones D, Thomas PK, et al. Acute motor neuropathy with antibodies to GM1 ganglioside. J Neurol. 1991 Dec;238(8):447-51. Resumen
60. Kuijf ML, Godschalk PC, Gilbert M, et al. Origin of ganglioside complex antibodies in Guillain-Barré syndrome. J Neuroimmunol. 2007 Aug;188(1-2):69-73. Resumen
61. Shu XM, Cai FC, Zhang XP. Carbohydrate mimicry of Campylobacter jejuni lipooligosaccharide is critical for the induction of anti-GM1 antibody and neuropathy. Muscle Nerve. 2006 Feb;33(2):225-31. Resumen
62. Yuki N, Susuki K, Koga M, et al. Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain-Barré syndrome. Proc Natl Acad Sci USA. 2004 Aug 3;101(31):11404-9.Texto completo Resumen
63. Brown WF, Feasby TE. Conduction block and denervation in Guillain-Barré polyneuropathy. Brain. 1984 Mar;107(Pt 1):219-39. Resumen
64. Feasby TE, Gilbert JJ, Brown WF, et al. An acute axonal form of Guillain-Barre polyneuropathy. Brain. 1986 Dec;109(Pt 6):1115-26. Resumen
65. Griffin JW, Li CY, Macko C, et al. Early nodal changes in the acute motor axonal neuropathy pattern of the Guillain-Barré syndrome. J Neurocytol. 1996 Jan;25(1):33-51. Resumen
66. Hafer-Macko C, Hsieh ST, Li CY, et al. Acute motor axonal neuropathy: an antibody-mediated attack on axolemma. Ann Neurol. 1996 Oct;40(4):635-44. Resumen
67. Safranek TJ, Lawrence DN, Kurland LT, et al. Reassessment of the association between Guillain-Barré syndrome and receipt of swine influenza vaccine in 1976-1977: results of a two-state study. Expert Neurology Group. Am J Epidemiol. 1991 May 1;133(9):940-51. Resumen
68. Ho TW, Hsieh ST, Nachamkin I, et al. Motor nerve terminal degeneration provides a potential mechanism for rapid recovery in acute motor axonal neuropathy after Campylobacter infection. Neurology. 1997 Mar;48(3):717-24. Resumen
69. Guillain-Barré Syndrome Study Group. Guillain-Barré syndrome: an Italian multicentre case-control study. Neurol Sci. 2000 Aug;21(4):229-34. Resumen
70. McCarthy N, Giesecke J. Incidence of Guillain-Barré syndrome following infection with Campylobacter jejuni. Am J Epidemiol. 2001 Mar 15;153(6):610-4.Texto completo Resumen
71. Cao-Lormeau VM, Blake A, Mons S, et al. Guillain-Barré syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet. 2016 Apr 9;387(10027):1531-9.Texto completo Resumen
72. World Health Organization. Assessment and management of Guillain-Barré syndrome in the context of Zika virus infection: interim guidance. Aug 2016 [internet publication].Texto completo
73. Public Health England. Guidance: Zika virus and Guillain-Barré syndrome. Aug 2017 [internet publication].Texto completo
74. Zheng X, Yu L, Xu Q, et al. Guillain-Barre syndrome caused by hepatitis E infection: case report and literature review. BMC Infect Dis. 2018 Jan 23;18(1):50.Texto completo Resumen
75. Stevens O, Claeys KG, Poesen K, et al. Diagnostic challenges and clinical characteristics of hepatitis E virus-associated Guillain-Barré syndrome. JAMA Neurol. 2017 Jan 1;74(1):26-33.Texto completo Resumen
76. Liu H, Ma Y. Hepatitis E virus-associated Guillain-Barre syndrome: Revision of the literature. Brain Behav. 2020 Jan;10(1):e01496.Texto completo Resumen
77. Amundson DE, Goodman JC. Hodgkin's disease in association with Guillain-Barré-Strohl syndrome: case report. Mil Med. 1983 Jun;148(6):512-3. Resumen
78. Halls J, Bredkjaer C, Friis ML. Guillain-Barré syndrome: diagnostic criteria, epidemiology, clinical course and prognosis. Acta Neurol Scand. 1988 Aug;78(2):118-22. Resumen
79. Hiew FL, Rajabally YA. Malignancy in Guillain-Barré syndrome: A twelve-year single-center study. J Neurol Sci. 2017 Apr 15;375:275-8. Resumen
80. Vigliani MC, Magistrello M, Polo P, et al. Risk of cancer in patients with Guillain-Barré syndrome (GBS). A population-based study. J Neurol. 2004 Mar;251(3):321-6. Resumen
81. Bertrand A, Kostine M, Barnetche T, et al. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med. 2015 Sep 4;13:211.Texto completo Resumen
82. Puwanant A, Isfort M, Lacomis D, et al. Clinical spectrum of neuromuscular complications after immune checkpoint inhibition. Neuromuscul Disord. 2019 Feb;29(2):127-33. Resumen
83. Hagberg L, Malmvall BE, Svennerholm L, et al. Guillain-Barré syndrome as an early manifestation of HIV central nervous system infection. Scand J Infect Dis. 1986;18(6):591-2. Resumen
84. Piette AM, Tusseau F, Vignon D, et al. Acute neuropathy coincident with seroconversion for anti-Lav/HTLV-III. Lancet. 1986 Apr 12;1(8485):852. Resumen
85. Vendrell J, Heredia C, Pujol M, et al. Guillain-Barré syndrome associated with seroconversion of anti-HTLV-III. Neurology. 1987 Mar;37(3):544. Resumen
86. Asbury AK. New concepts of Guillain-Barré syndrome. J Child Neurol. 2000 Mar;15(3):183-91. Resumen
87. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol. 1990;27 suppl:S21-4. Resumen
88. Van der Meché FG, Van Doorn PA, Meulstee J, et al. Diagnostic and classification criteria for the Guillain-Barré syndrome. Eur Neurol. 2001;45(3):133-9. Resumen
89. Fokke C, van den Berg B, Drenthen J, et al. Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria. Brain. 2014 Jan;137(pt 1):33-43. Resumen
90. Zaeem Z, Siddiqi ZA, Zochodne DW. Autonomic involvement in Guillain-Barré syndrome: an update. Clin Auton Res. 2019 Jun;29(3):289-99.Texto completo Resumen
91. Moulin DE, Hagen N, Feasby TE, et al. Pain in Guillain-Barré syndrome. Neurology. 1997 Feb;48(2):328-31. Resumen
92. Wu X, Shen D, Li T, et al. Distinct clinical characteristics of pediatric Guillain-Barré syndrome: a comparative study between children and adults in northeast China. PLoS One. 2016 Mar 14;11(3):e0151611.Texto completo Resumen
93. Sakakibara R, Uchiyama T, Kuwabara S, et al. Prevalence and mechanism of bladder dysfunction in Guillain-Barré Syndrome. Neurourol Urodyn. 2009;28(5):432-7. Resumen
94. Teitelbaum JS, Borel CO. Respiratory dysfunction in Guillain-Barré syndrome. Clin Chest Med. 1994 Dec;15(4):705-14. Resumen
95. Albers JW, Kelly JJ Jr. Acquired inflammatory demyelinating polyneuropathies: clinical and electrodiagnostic features. Muscle Nerve. 1989 Jun;12(6):435-51. Resumen
96. McKhann GM, Cornblath DR, Griffin JW, et al. Acute motor axonal neuropathy: a frequent cause of acute flaccid paralysis in China. Ann Neurol. 1993 Apr;33(4):333-42. Resumen
97. Hiraga A, Mori M, Ogawara K, et al. Differences in patterns of progression in demyelinating and axonal Guillain-Barré syndromes. Neurology. 2003 Aug 26;61(4):471-4. Resumen
98. Willison HJ, Veitch J, Paterson G, et al. Miller Fisher syndrome is associated with serum antibodies to GQ1b ganglioside. J Neurol Neurosurg Psychiatry. 1993 Feb;56(2):204-6.Texto completo Resumen
99. Teener JW. Miller Fisher's syndrome. Semin Neurol. 2012 Nov;32(5):512-6. Resumen
100. Mori M, Kuwabara S, Koga M, et al. IgG anti-GQ1b positive acute ataxia without ophthalmoplegia. J Neurol Neurosurg Psychiatry. 1999 Nov;67(5):668-70.Texto completo Resumen
101. Thompson HS. Adie's syndrome: some new observations. Trans Am Ophthalmol Soc. 1977;75:587-626.Texto completo Resumen
102. Caccavale A, Mignemi L. Acute onset of a bilateral areflexical mydriasis in Miller-Fisher syndrome: a rare neuro-ophthalmologic disease. J Neuroophthalmol. 2000 Mar;20(1):61-2. Resumen
103. Mori M, Kuwabara S, Fukutake T, et al. Clinical features and prognosis of Miller Fisher syndrome. Neurology. 2001 Apr 24;56(8):1104-6. Resumen
104. Sekiguchi Y, Mori M, Misawa S, et al. How often and when Fisher syndrome is overlapped by Guillain-Barré syndrome or Bickerstaff brainstem encephalitis? Eur J Neurol. 2016 Jun;23(6):1058-63. Resumen
105. Overell JR, Hsieh ST, Odaka M, et al. Treatment for Fisher syndrome, Bickerstaff's brainstem encephalitis and related disorders. Cochrane Database Syst Rev. 2007 Jan 24;(1):CD004761.Texto completo Resumen
106. Odaka M, Yuki N, Yamada M, et al. Bickerstaff's brainstem encephalitis: clinical features of 62 cases and a subgroup associated with Guillain-Barré syndrome. Brain. 2003 Oct;126(Pt 10):2279-90.Texto completo Resumen
107. Yuki N, Sato S, Tsuji S, et al. An immunologic abnormality common to Bickerstaff's brain stem encephalitis and Fisher's syndrome. J Neurol Sci. 1993 Aug;118(1):83-7. Resumen
108. Hughes RA, Cornblath DR. Guillain-Barré syndrome. Lancet. 2005 Nov 5;366(9497):1653-66. Resumen
109. Al-Din AN, Anderson M, Bickerstaff ER, et al. Brainstem encephalitis and the syndrome of Miller Fisher: a clinical study. Brain. 1982 Sep;105 (Pt 3):481-95. Resumen
110. Willison HJ, Yuki N. Peripheral neuropathies and anti-glycolipid antibodies. Brain. 2002 Dec;125(Pt 12):2591-625.Texto completo Resumen
111. Van Sorge NM, van der Pol WL, Jansen MD, et al. Pathogenicity of anti-ganglioside antibodies in the Guillain-Barré syndrome. Autoimmun Rev. 2004 Feb;3(2):61-8. Resumen
112. Hadden RD, Cornblath DR, Hughes RA, et al. Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barre Syndrome Trial Group. Ann Neurol. 1998 Nov;44(5):780-8. Resumen
113. Van den Bergh PY, Piéret F. Electrodiagnostic criteria for acute and chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve. 2004 Apr;29(4):565-74. Resumen
114. Rajabally YA, Durand MC, Mitchell J, et al. Electrophysiological diagnosis of Guillain-Barré syndrome subtype: could a single study suffice? J Neurol Neurosurg Psychiatry. 2015 Jan;86(1):115-9. Resumen
115. Ibrahim J, Grapperon AM, Manfredonia F, et al. Serial electrophysiology in Guillain-Barré syndrome: a retrospective cohort and case-by-case multicentre analysis. Acta Neurol Scand. 2018 Mar;137(3):335-40. Resumen
116. Uncini A, Kuwabara S. The electrodiagnosis of Guillain-Barré syndrome subtypes: where do we stand? Clin Neurophysiol. 2018 Dec;129(12):2586-93. Resumen
117. Wong AH, Umapathi T, Nishimoto Y, et al. Cytoalbuminologic dissociation in Asian patients with Guillain-Barré and Miller Fisher syndromes. J Peripher Nerv Syst. 2015 Mar;20(1):47-51. Resumen
118. DiCapua DB, Lakraj AA, Nowak RJ, et al. Relationship between cerebrospinal fluid protein levels and electrophysiologic abnormalities in Guillain-Barré syndrome. J Clin Neuromuscul Dis. 2015 Dec;17(2):47-51. Resumen
119. Lavi R, Yarnitsky D, Rowe JM, et al. Standard vs atraumatic Whitacre needle for diagnostic lumbar puncture: a randomized trial. Neurology. 2006 Oct 24;67(8):1492-4. Resumen
120. Arendt K, Demaerschalk BM, Wingerchuk DM, Camann W. Atraumatic lumbar puncture needles: after all these years, are we still missing the point? Neurologist. 2009 Jan;15(1):17-20. Resumen
121. Nath S, Koziarz A, Badhiwala JH, et al. Atraumatic versus conventional lumbar puncture needles: a systematic review and meta-analysis. Lancet. 2018 Mar 24;391(10126):1197-204. Resumen
122. Rochwerg B, Almenawer SA, Siemieniuk RAC, et al. Atraumatic (pencil-point) versus conventional needles for lumbar puncture: a clinical practice guideline. BMJ. 2018 May 22;361:k1920.Texto completo Resumen
123. Ahmed SV, Jayawarna C, Jude E. Post lumbar puncture headache: diagnosis and management. Postgrad Med J. 2006 Nov;82(973):713-6.Texto completo Resumen
124. Arevalo-Rodriguez I, Ciapponi A, Roqué i Figuls M, et al. Posture and fluids for preventing post-dural puncture headache. Cochrane Database Syst Rev. 2016 Mar 7;(3):CD009199.Texto completo Resumen
125. Lawn ND, Fletcher DD, Henderson RD, et al. Anticipating mechanical ventilation in Guillain-Barré syndrome. Arch Neurol. 2001 Jun;58(6):893-8.Texto completo Resumen
126. Sundar U, Abraham E, Gharat A, et al. Neuromuscular respiratory failure in Guillain-Barré syndrome: evaluation of clinical and electrodiagnostic predictors. J Assoc Physicians India. 2005 Sep;53:764-8. Resumen
127. Sharshar T, Chevret S, Bourdain F, et al. Early predictors of mechanical ventilation in Guillain-Barré syndrome. Crit Care Med. 2003 Jan;31(1):278-83. Resumen
128. Green C, Baker T, Subramaniam A. Predictors of respiratory failure in patients with Guillain-Barré syndrome: a systematic review and meta-analysis. Med J Aust. 2018 Mar 5;208(4):181-8. Resumen
129. Walgaard C, Lingsma HF, Ruts L, et al. Prediction of respiratory insufficiency in Guillain-Barré syndrome. Ann Neurol. 2010 Jun;67(6):781-7. Resumen
130. Hiraga A, Kuwabara S. Early prediction of prognosis in Guillain-Barré syndrome. Lancet Neurol. 2007 Jul;6(7):572-3. Resumen
131. Yoshikawa K, Kuwahara M, Morikawa M, et al. Varied antibody reactivities and clinical relevance in anti-GQ1b antibody-related diseases. Neurol Neuroimmunol Neuroinflamm. 2018 Nov;5(6):e501.Texto completo Resumen
132. Oomes PG, van der Meché FG, Kleyweg RP. Liver function disturbances in Guillain-Barré syndrome: a prospective longitudinal study in 100 patients. Dutch Guillain-Barré Study Group. Neurology. 1996 Jan;46(1):96-100. Resumen
133. Durand MC, Porcher R, Orlikowski D, et al. Clinical and electrophysiological predictors of respiratory failure in Guillain-Barré syndrome: a prospective study. Lancet Neurol. 2006 Dec;5(12):1021-8. Resumen
134. Ropper AH. The Guillain-Barré syndrome. N Engl J Med. 1992;326:1130-1136. Resumen
135. Wakerley BR, Yuki N. Polyneuritis cranialis: oculopharyngeal subtype of Guillain-Barré syndrome. J Neurol. 2015 Sep;262(9):2001-12. Resumen
136. Uncini A, Notturno F, Kuwabara S. Hyper-reflexia in Guillain-Barré syndrome: systematic review. J Neurol Neurosurg Psychiatry. 2020 Mar;91(3):278-84. Resumen
137. Fuller GN, Jacobs JM, Lewis PD, et al. Pseudoaxonal Guillain-Barré syndrome: severe demyelination mimicking axonopathy. A case with pupillary involvement. J Neurol Neurosurg Psychiatry. 1992 Nov;55(11):1079-83.Texto completo Resumen
138. Rougé A, Lemarié J, Gibot S, et al. Long-term impact after fulminant Guillain-Barré syndrome, case report and literature review. Int Med Case Rep J. 2016;9:357-63.Texto completo Resumen
139. Thomas PD. The differential diagnosis of fixed dilated pupils: a case report and review. Crit Care Resusc. 2000 Mar;2(1):34-7. Resumen
140. van den Berg B, Walgaard C, Drenthen J, et al. Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol. 2014 Aug;10(8):469-82.Texto completo Resumen
141. Soar J, Böttiger BW, Carli P, et al. European Resuscitation Council Guidelines 2021: adult advanced life support. Resuscitation. 2021 Apr;161:115-51.Texto completo Resumen
142. Colquhoun MC, Handley AJ, Evans TR, eds. ABC of resuscitation. 5th ed. Wiley-Blackwell; 2004.
143. Chrimes N, Higgs A, Hagberg CA, et al. Preventing unrecognised oesophageal intubation: a consensus guideline from the Project for Universal Management of Airways and international airway societies. Anaesthesia. 2022 Aug 17 [Epub ahead of print].Texto completo Resumen
144. Gorson KC, Ropper AH, Muriello MA, et al. Prospective evaluation of MRI lumbosacral nerve root enhancement in acute Guillain-Barré syndrome. Neurology. 1996 Sep;47(3):813-7. Resumen
145. Doets AY, Jacobs BC, van Doorn PA. Advances in management of Guillain-Barré syndrome. Curr Opin Neurol. 2018 Oct;31(5):541-50. Resumen
146. Razali SNO, Arumugam T, Yuki N, et al. Serial peripheral nerve ultrasound in Guillain-Barré syndrome. Clin Neurophysiol. 2016 Feb;127(2):1652-6. Resumen
147. Ropper AH, Marmarou A. Mechanism of pseudotumor in Guillain-Barré syndrome. Arch Neurol. 1984 Mar;41(3):259-61. Resumen
148. Fross RD, Daube JR. Neuropathy in the Miller Fisher syndrome: clinical and electrophysiologic findings. Neurology. 1987 Sep;37(9):1493-8. Resumen
149. Hughes RA, Newsom-Davis JM, Perkin GD, et al. Controlled trial of prednisolone in acute polyneuropathy. Lancet. 1978;2:750-753. Resumen
150. Hughes RA, Wijdicks EF, Benson E, et al; Multidisciplinary Consensus Group. Supportive care for patients with Guillain-Barré syndrome. Arch Neurol. 2005 Aug;62(8):1194-8.Texto completo Resumen
151. Soar J, Böttiger BW, Carli P, et al. European Resuscitation Council Guidelines 2021: Adult advanced life support. Resuscitation. 2021 Apr;161:115-151.Texto completo Resumen
152. Soar J, Böttiger BW, Carli P, et al. European Resuscitation Council Guidelines 2021: Adult advanced life support. Resuscitation. 2021 Apr;161:115-151.Texto completo Resumen
153. Truax B. Autonomic disturbances in Guillain-Barré syndrome. Semin Neurol. 1984;4(4):462-8.
154. Lawn ND, Wijdicks EF. Fatal Guillain-Barré syndrome. Neurology. 1999 Feb;52(3):635-8. Resumen
155. Zochodne DW. Autonomic involvement in Guillain-Barré syndrome: a review. Muscle Nerve. 1994 Oct;17(10):1145-55. Resumen
156. Burns TM, Lawn ND, Low PA, et al. Adynamic ileus in severe Guillain-Barré syndrome. Muscle Nerve. 2001 Jul;24(7):963-5. Resumen
157. Hughes RA, Wijdicks EF, Barohn R, et al. Practice parameter: immunotherapy for Guillain-Barré syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2003 Sep 23;61(6):736-40.Texto completo Resumen
158. Perez EE, Orange JS, Bonilla F, et al. Update on the use of immunoglobulin in human disease: a review of evidence. J Allergy Clin Immunol. 2017 Mar;139(3s):S1-46.Texto completo Resumen
159. French Cooperative Group on Plasma Exchange in Guillain-Barré syndrome. Efficiency of plasma exchange in Guillain-Barré syndrome: role of replacement fluids. Ann Neurol. 1987 Dec;22(6):753-61. Resumen
160. Osterman PO, Fagius J, Lundemo G, et al. Beneficial effects of plasma exchange in acute inflammatory polyradiculoneuropathy. Lancet. 1984 Dec 8;2(8415):1296-9. Resumen
161. Donofrio PD, Berger A, Brannagan TH 3rd, et al. Consensus statement: the use of intravenous immunoglobulin in the treatment of neuromuscular conditions report of the AANEM ad hoc committee. Muscle Nerve. 2009 Nov;40(5):890-900. Resumen
162. Hughes RA, Brassington R, Gunn AA, et al. Corticosteroids for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2016 Oct 24;(10):CD001446.Texto completo Resumen
163. Guzey Aras Y, Tanik O, Dogan Güngen B, et al. Patient characteristics and the effects of intravenous immunoglobulin in patients with Guillain-Barre syndrome. Ideggyogy Sz. 2016 Nov 30;69(11-12):389-95. Resumen
164. Walgaard C, Jacobs BC, Lingsma HF, et al. Second intravenous immunoglobulin dose in patients with Guillain-Barré syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2021 Apr;20(4):275-83. Resumen
165. McKhann GM, Griffin JW, Cornblath DR, et al. Plasmapheresis and Guillain-Barré syndrome: analysis of prognostic factors and the effect of plasmapheresis. Ann Neurol. 1988 Apr;23(4):347-53. Resumen
166. Khan F, Amatya B. Rehabilitation interventions in patients with acute demyelinating inflammatory polyneuropathy: a systematic review. Eur J Phys Rehabil Med. 2012 Sep;48(3):507-22.Texto completo Resumen
167. Hughes RA, Swan AV, Raphael JC, et al. Immunotherapy for Guillain-Barré syndrome: a systematic review. Brain. 2007 Sep;130(Pt 9):2245-57. Resumen
168. Raphael JC, Masson C, Morice V, et al. The Landry-Guillain-Barré syndrome. Study of prognostic factors in 223 cases [in French]. Rev Neurol (Paris). 1986;142(6-7):613-24. Resumen
169. Raphael JC, Chevret S, Harboun M, et al. Intravenous immune globulins in patients with Guillain-Barré syndrome and contraindications to plasma exchange: 3 days versus 6 days. J Neurol Neurosurg Psychiatry. 2001 Aug;71(2):235-8.Texto completo Resumen
170. Motamed-Gorji N, Matin N, Tabatabaie O, et al. Biological drugs in Guillain-Barré syndrome: an update. Curr Neuropharmacol. 2017;15(7):938-50.Texto completo Resumen
171. Yamaguchi N, Misawa S, Sato Y, et al; JET-GBS Group. A prospective, multicenter, randomized phase II study to evaluate the efficacy and safety of eculizumab in patients with Guillain-Barré syndrome (GBS): protocol of Japanese eculizumab trial for GBS (JET-GBS). JMIR Res Protoc. 2016 Nov 7;5(4):e210.Texto completo Resumen
172. Misawa S, Kuwabara S, Sato Y, et al. Safety and efficacy of eculizumab in Guillain-Barré syndrome: a multicentre, double-blind, randomised phase 2 trial. Lancet Neurol. 2018 Jun;17(6):519-29. Resumen
173. Doets AY, Hughes RA, Brassington R, et al. Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2020 Jan 25;1(1):CD008630.Texto completo Resumen
174. Al-Salama ZT. Imlifidase: First Approval. Drugs. 2020 Nov;80(17):1859-64. Resumen
175. ClinicalTrials.gov. A study of imlifidase in patients with Guillain-Barré syndrome. Sep 2021 [internet publication].Texto completo
176. Fletcher DD, Lawn ND, Wolter TD, et al. Long-term outcome in patients with GBS requiring mechanical ventilation. Neurology. 2000 Jun 27;54(12):2311-5. Resumen
177. Chiò A, Cocito D, Leone M, et al; Piemonte and Valle d'Aosta Register for Guillain-Barré Syndrome. Guillain-Barré Syndrome: a prospective, population-based incidence and outcome survey. Neurology. 2003 Apr 8;60(7):1146-50. Resumen
178. Stewart GJ, Pollard JD, McLeod JG, et al. Calcium homeostasis in immobilization: an example of resorptive hypercalcinuria. N Engl J Med. 1982 May 13;306(19):1136-40. Resumen
179. Meythaler JM, Korkor AB, Nanda T, et al. Immobilization hypercalcemia associated with Landry-Guillain-Barré syndrome. Successful therapy with combined calcitonin and etidronate. Arch Intern Med. 1986 Aug;146(8):1567-71. Resumen
180. Emmanuel AV, Shand AG, Kamm MA. Erythromycin for the treatment of chronic intestinal pseudo-obstruction: description of six cases with a positive response. Aliment Pharmacol Ther. 2004 Mar 15;19(6):687-94. Resumen
181. Ponec RJ, Saunders MD, Kimmey MB. Neostigmine for the treatment of acute colonic pseudo-obstruction. N Engl J Med. 1999 Jul 15;341(3):137-41.Texto completo Resumen
182. Gracey DR, McMichan JC, Divertie MB, et al. Respiratory failure in Guillain-Barré syndrome. a 6-year experience. Mayo Clin Proc. 1982 Dec;57(12):742-6. Resumen
El uso de este contenido está sujeto a nuestra cláusula de exención de responsabilidad